LNTH Research and Charts

LNTH - Lantheus Holdings Inc (Healthcare: Diagnostics & Research)

Projected Earnings Date: 2025-08-06 (Delayed quote data 2025-05-09)

Last 81.74	Change ⇑ +1.30 (+1.62%)	Volume 1,561,274
	Open 80.44	High 82.21	Low 79.55

8EMA (Daily) 92.11	40EMA (Daily) 97.40	50EMA (Daily) 97.18	STO (Daily) 36.436	MACD Hist (Daily) -5.646
8EMA (Weekly) 96.396	40EMA (Weekly) 93.60	50EMA (Weekly) 92.16	STO (Weekly) 63.501	MACD Hist (Weekly) -0.720


Company Profile
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. The company's portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacy and directly to hospitals and clinics predominantly in the United States.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.